• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

FDA grants priority review for Daiichi Sankyo’s AML medicine

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Oct 25, 2022 at 11:02: AM
via The US Food and Drug Administration (FDA) has granted priority review for Daiichi Sankyo’s quizartinib along with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy to treat newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).

article source
 

<



Similar threads

cafead
FDA grants priority review for Daiichi Sankyo-Merck’s lung cancer therapy
Replies
0
Views
187
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA grants priority review for Takeda and HUTCHMED’s fruquintinib NDA
Replies
0
Views
263
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA accepts Iveric Bio&#039;s NDA, grants priority review for GA drug
Replies
0
Views
197
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA grants priority reviews for Pfizer&#039;s Prevnar 20 for kids and Roche lymphoma candidate
Replies
0
Views
166
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA grants priority review to Takeda’s BLA for dengue vaccine candidate
Replies
0
Views
219
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote